Navigation Links
Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors." commented Dr. Barrie Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), incre
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive Intelligence ... and marketplace changes. CI leaders who adjust will succeed, ... In a new Best Practices, LLC study CI leaders ... insights, including: - Use secondary research whenever ... research - Internal staff who are creative ...
(Date:8/29/2014)... SAN DIEGO , Aug. 29, 2014 /PRNewswire/ ... an emerging biopharmaceutical company, announced today that Santosh ... will be leaving the Company, for personal reasons, ... the Chief Medical Officer of Aires Pharmaceuticals, which ... Vetticaden,s former responsibilities as the Company,s interim Chief ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... N.J., July 15, 2011 Crestor and ... to lower "bad cholesterol". Both drugs are classified as ... HMG-CoA reductase. This group of drugs has had a ... Crestor and Zocor, touted as a "super statin" before ...
... -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, ... as Chief Executive Officer. Mr. Mathers has ... marketing experience in the life sciences and medical device ... for the Biotechnology Industry Organization (BIO), and as chairman ...
Cached Medicine Technology:Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis 2CoLucid Appoints Thomas P. Mathers as Chief Executive Officer 2
(Date:8/30/2014)... 2014 Seniors Guide, the comprehensive guide to ... on Alzheimer’s Disease, Dementia, and Memory Loss . , ... of being diagnosed with the Alzheimer’s, inspired Seniors Guide writers ... Me”. The movie, out on October 14, 2014, shows ... diagnosis of the disease – which inspires a final tour ...
(Date:8/30/2014)... 2014 Insomnia causes disturbances in every aspect ... they unknowingly developed insomnia and the steps often used to ... Tune in to the show at this link: Dr. ... on August 30, and will be podcasted at this ... to DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. ...
(Date:8/30/2014)... Dotinga HealthDay Reporter FRIDAY, ... patients operated on for broken bones or other orthopedic trauma ... finds. Less-educated patients and patients who had used ... "doctor shoppers," said study lead author Dr. Brent Morris, a ... the study suggests that doctors aren,t talking to one another ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team ... Arizona is pleased to report having saved a client ... among many cases where Hastings and Hastings has tailored ... a greater portion of their settlement or recovery. The ... positive solution for Arizona car accident victims is achievable ...
(Date:8/30/2014)... plant-based medication commonly used to treat gout, before ... reducing potential complications from this type of surgery, ... adverse effects, according to a study published by ... early online to coincide with its presentation at ... complications after cardiac surgery include postpericardiotomy syndrome (the ...
Breaking Medicine News(10 mins):Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Medication shows mixed results in reducing complications from cardiac surgery 2
... ... Media Services, the largest production/post-production company in the Mid-Atlantic region, acquires premiere Blu-ray ... Clients include National Geographic Films, Discovery Networks and various documentary filmmakers. , ... (PRWEB) June ...
... ... a renewable resource. , ... June 26, 2010 -- Laser and copier toners use over 146,000,000 gallons of oil per ... or Forestry products, therefore, eliminating the need for petroleum products. The term bio-product is ...
... ... will prioritize the health of the world’s women and children. UN Foundation CEO Kathy Calvin ... and child health. , ... DC (Vocus) June 25, 2010 -- As world leaders come together today in Canada for ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, June 25 ... off the throbbing in her back and leg. An Army ... herself physically and mentally. But as her Iraq ... like she was being stabbed. She could hardly sit, stand ...
... , ... American Red Cross of Greater Chicago , ... Oak Brook, IL (Vocus) June 25, 2010 -- AthletiCo Physical and Occupational ... joined with Phones 4 Charity to reduce, reuse, and recycle. Phones 4 Charity ...
... The American Physical Society, a leading organization of physicists, ... energy technologies that will strengthen energy security and reduce ... exploration as evidenced by the BP oil spill. ... the history of the nation has caused extraordinary ...
Cached Medicine News:Health News:Henninger Media Services Now Offers Hollywood-Quality Blu-ray Products 2Health News:Henninger Media Services Now Offers Hollywood-Quality Blu-ray Products 3Health News:Great Office Buys Announces the Addition of Elite Brand Bio-Based Toners to their Product Line 2Health News:United Nations Foundation Commends G8 Leaders for Accelerating Support for Proven Interventions to Improve Women's and Children's Health 2Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 2Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 3Health News:AthletiCo Physical Therapy Holds July Cell Phone Drive 2Health News:APS urges greater federal investment in energy research 2
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
... is an advanced three-part inflatable prosthesis consisting of ... placed in the scrotum and a pair of ... simulates the look and performance of a natural ... technology, the AMS 700 Series now features the ...
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
Medicine Products: